Refining the Primrose syndrome phenotype: A study of five patients with ZBTB20 de novo variants and a review of the literature by Cleaver, Ruth et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/118555/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Cleaver, Ruth, Berg, Jonathan, Craft, Emily, Foster, Alison, Gibbons, Richard J., Hobson, Emma,
Lachlan, Katherine, Naik, Swati, Sampson, Julian R., Sharif, Saba, Smithson, Sarah, Parker,
Michael J. and Tatton-Brown, Katrina 2019. Refining the Primrose syndrome phenotype: A study of
five patients with ZBTB20 de novo variants and a review of the literature. American Journal of
Medical Genetics Part A 179 (3) , pp. 344-349. 10.1002/ajmg.a.61024 file 
Publishers page: http://dx.doi.org/10.1002/ajmg.a.61024 <http://dx.doi.org/10.1002/ajmg.a.61024>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
  1 
REFINING THE PRIMROSE SYNDROME PHENOTYPE: A STUDY OF FIVE PATIENTS WITH ZBTB20 DE 
NOVO VARIANTS AND A REVIEW OF THE LITERATURE 
 
Ruth Cleaver1, Jonathan Berg2, Emily Craft3, Alison Foster4, Richard Gibbons5, Emma Hobson6, 
Katherine Lachlan7, Swati Naik4 , Julian Sampson8, Saba Sharif4, Sarah Smithson9, Deciphering 
Developmental Disorders Study10, Michael J. Parker11, Katrina Tatton-Brown1,12 
 
1. South West Thames Regional Genetics Service, St. George’s University Hospitals NHS Foundation 
Trust, London, UK 
2. East of Scotland Regional Genetics Service, Dundee, UK 
3. Department of Clinical Genetics, University Hospitals of Leicester NHS Trust, Leicester, UK 
4. West Midlands Regional Genetics Service, Birmingham, UK  
5. Oxford Centre for Genomic Medicine, Oxford, UK   
6. Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds Teaching Hospitals NHS 
Trust, Leeds, UK 
7. Wessex Clinical Genetics Service, Southampton, UK 
8. All Wales Medical Genetics Service, Cardiff, UK 
9. Bristol Regional Genetics Service, Bristol, UK 
10. Deciphering Developmental Disorders Study, Wellcome Trust Sanger Institute, Cambridge, UK 
11. Sheffield Children’s NHS Foundation Trust, Sheffield Clinical Genetics Service, Sheffield, South 
Yorkshire, UK 
12. St. George’s University of London, UK 
 
Abstract 
Primrose syndrome is a rare autosomal dominant condition caused by heterozygous missense 
variants within ZBTB20. Through an exome sequencing approach (as part of the Deciphering 
Developmental Disorders (DDD) study) we have identified five unrelated individuals with 
previously unreported, de novo ZBTB20 pathogenic missense variants. All five missense 
variants targeted the C2H2 zinc finger domains. This genotype-up approach has allowed further 
refinement of the Primrose syndrome phenotype. Major characteristics (>90% individuals) 
include an intellectual disability (most frequently in the moderate range), a recognizable facial 
appearance and brain MRI abnormalities, particularly abnormalities of the corpus callosum. 
Other frequent clinical associations (in 50-90% individuals) include sensorineural hearing loss 
(83%), hypotonia (78%), cryptorchidism in males (75%), macrocephaly (72%), behavioral issues 
(67%) and dysplastic/hypoplastic nails (53%). Based upon these clinical data we discuss our 
current management of patients with Primrose syndrome.  
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Introduction 
Primrose Syndrome (OMIM 259050), first described in 1982 by David Primrose, has previously 
been associated with a moderate to severe intellectual disability, a recognisable facial 
appearance with deep set eyes, narrow, often down-slanting palpebral fissures, ptosis, 
depressed nasal bridge and macrocephaly with or without tall stature (1-12). Additional reported 
clinical features include muscle wasting, calcified pinnae, hearing loss, cataracts, hypothyroidism 
(6,9), torus palatinus (a benign osseous elevation usually found on the midline of the hard palate) 
(1,2,5,6), and sparse body and facial hair (1,2,3,4,5,8).   
In 2014, heterozygous pathogenic variants within ZBTB20 were shown to cause Primrose 
syndrome (12). ZBTB20, located at chromosome position 3q13.31, encodes one of a family of 
POK [POZ (pox virus and zinc finger) and Kruppel] proteins which acts as a transcriptional 
repressor and has a role in glucose metabolism, postnatal growth and neurogenesis (13,14,15). 
ZBTB20 has five C2H2 zinc finger domains (ZNFI-ZNFV) and an N-terminal BTB (Broad Complex, 
Tramtrack, Bric a brac) domain that mediate interaction with DNA (figure 1a, 13).   
To date, 14 of 15 Primrose syndrome reported ZBTB20 pathogenic variants are missense variants 
clustering within the first (three variants), second (six variants) and third (two variants) zinc finger 
domains and the linker region between the first two motifs (three variants, figure 1a, 
supplementary table 1, refs). Functional assays have supported a dominant negative mechanism 
of disease whereby missense variants result in a stable but dysfunctional protein with defective 
DNA binding (12). In contrast, haploinsufficiency of ZBTB20 causing the 3q13.31 microdeletion 
syndrome (OMIM 615433), has been reported to cause a similar but distinct condition also 
characterized by increased growth but without many of the Primrose syndrome clinical 
associations including the recognizable facial appearance, calcified pinnae and muscle wasting 
(16,17).  
Here we report five patients with de novo ZBTB20 pathogenic missense variants, identified 
through trio-based exome sequencing. This genotype-up approach has replicated the previous 
finding that ZBTB20 missense variants target the zinc finger domains and has allowed a non-
biased refinement of the Primrose syndrome phenotype. 
 
Methods 
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The study was approved by the UK Research Ethics Committee (10/H0305/83), granted by the 
Cambridge South Research Ethics Committee. Informed consent was obtained from all families. 
Seven patients with de novo ZBTB20 variants were identified through the Deciphering 
Developmental Disorders (DDD) Study using a trio-based exome sequencing strategy and 
methods as previously described (18). Five patients had missense variants, predicted to be 
pathogenic according to American College of Medical Genetics and Genomics (ACMG criteria PS2, 
PM1, PM2, PP2 and PP3 (19)) with evidence detailed in supplementary table 2. These five 
missense variants targeted the first, second and third zinc fingers (ZNFI, ZNFII and ZNFIII). None 
had previously been reported.  
The remaining two patients with de novo ZBTB20 variants were not included in the current study: 
one patient because there was insufficient evidence to support pathogenicity of the variant and 
the other because the patient additionally had a maternally inherited FLNA likely pathogenic 
variant resulting in a compound phenotype. It was therefore unclear which clinical features were 
attributable to the ZBTB20 variant and which to the FLNA variant.   
Clinical data for the five patients with the single de novo pathogenic missense ZBTB20 variants 
were obtained through face to face review by one of the authors, all experienced 
dysmorphologists, and a standardized proforma. Photographs were requested in all five 
individuals and received, with accompanying consent to publish, from ** families.  
Results 
Clinical details are summarized in table 1. Detailed case reports are shown below: 
Patient 1 (DDD 273936) 
Patient 1, female, had a de novo ZBTB20 c.1749C>G p.(Cys583Trp) pathogenic variant.  She was 
born at 38 weeks gestation following an uncomplicated pregnancy.  Her birth weight was 2.9kg 
(0.3 standard deviations below the mean, -0.3SD) with a head circumference of 36cm (+2.1SD).  
At the age of 3 years, her height was 99cm (-0.5SD), weight was 15kg (-0.6SD) and head 
circumference was 51.5cm (+0.4SD).  Patient 1 had a severe learning disability and was delayed 
in the attainment of her developmental milestones: she sat between 6 and 7 years of age, 
crawled aged 7, she was not walking when reviewed at the age of 9 years and remained non-
verbal.  She had hypothyroidism, hypotonia and brachycephaly. A brain MRI scan identified 
colpocephaly and agenesis of the corpus callosum.  
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Patient 2 (DDD 303448) 
Patient 2, male, had a de novo ZBTB20 c.1850T>C p.(Leu617Ser) pathogenic variant.  He was one 
of twins born at 37+6 weeks gestation following an uncomplicated pregnancy.  Birth weight was 
2.3kg (-2.1SD) with a head circumference of 35.4cm (+0.4SD).  At 3.9 years, his height was 97cm 
(-1.5SD), weight was 12.3kg (-2.5SD), and head circumference was 53.5cm (+1.9SD).  Patient 2 
sat unsupported at 21 months, was not able to walk (at 3.9 years) and began to babble at 34 
months.  He had a tendency to head bang when frustrated.  Patient 2 had a moderate-severe 
congenital sensorineural hearing loss, a small patent foramen ovale and generalised hypotonia, 
more prominent in the lower limbs.  He had had one focal seizure.  He had hypermetropia, 
astigmatism and a convergent squint.  Dysmorphic features included low-set ears, flat mid-face 
with prominent forehead, deep-set eyes with down slanting palpebral fissures and a thin upper 
lip (figure 1b).  A brain MRI scan demonstrated partial agenesis of the corpus callosum.  
Patient 3 (DDD 273033) 
Patient 3, female, had a de novo ZBTB20 c.1879A>G p.(Thr627Ala) pathogenic variant.  She was 
born at 39 weeks gestation following a normal pregnancy with a birth weight of 2.98kg (-0.5SD).  
There were some difficulties establishing feeding in the early neonatal period but no other 
significant concerns.  At the age of 2.3 years, her height was 85cm (-0.8SD), weight was 10.9kg (-
1.2SD) and head circumference was 50.5 cm (+1SD).  Patient 3 was slow to reach her 
developmental milestones; she sat at 6 months, walked aged 3-4 years, and spoke her first words 
between 2.5 and 3 years.  She had a moderate learning disability.  She had mild generalised 
hypotonia in infancy progressing to truncal hypotonia in adolescence with increased tone and 
reflexes in the left leg.  Additional medical problems included kyphoscoliosis, mixed conductive 
and sensorineural hearing loss, hypermetropia with recurrent blepharoconjunctivitis and raised 
urinary calcium with possible nephrocalcinosis.  Patient 3 had joint hypermobility with soft, 
doughy skin, cutis marmorata and dysplastic nails.  She had a narrow mouth, pointed chin, and 
upslanting palpebral fissures (figure 1b). Dentition was poor with delayed secondary dentition.  
A brain MRI scan was unremarkable and bone age was delayed (the bone age was 2 years at 
chronological age of 3 years 4 months). 
Patient 4 (DDD 263871) 
Patient 4, male, had a de novo mosaic ZBTB20 c.1943C>T p.(Ser648Phe) pathogenic variant.  He 
was born at term following an uncomplicated pregnancy with a birth weight of 5.3kg (+3.4SD).  
At 11.25 years, his height was 154.5cm (+0.9SD), weight was 73.7kg (+2.6SD), and head 
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circumference was 61cm (+5SD).  He sat at 7 months, walked at 12 months and developed speech 
at 3-4 years.  He had a moderate learning difficulty.  He was a poor sleeper, had a poor working 
memory and a tendency to temper tantrums.  He had bilateral cryptorchidism, a convergent 
squint and sensorineural hearing loss.  He had narrrow, downslanting palpebral fissures and a 
high arched palate (figure 1b).  A brain MRI scan identified a Chiari malformation.  
Patient 5 (DDD 280375) 
Patient 5, male, had a de novo ZBTB20 c.1967A>G p.(His656Arg) pathogenic variant.  He was born 
at 41+5 weeks gestation following an uncomplicated pregnancy.  He was delivered via an 
emergency caesarean section for fetal distress and had a birth weight of 2.6kg (-2.1SD).  There 
were no immediate postnatal concerns.  At 13.4 years of age, his height was 154cm (-1SD), weight 
was 68.3kg (+1.4SD), and head circumference was 59cm (+2.8SD).  He sat at 10 months, walked 
aged 3-4 years, and developed his first words between 2.5 and 3 years of age.  He had a moderate 
learning difficulty.  He had moderate bilateral congenital sensorineural hearing loss, obesity 
(associated with hyperphagia), central and peripheral hypotonia and a marked lumbar lordosis.  
He had mild camptodactyly, hypoplastic 5th toe nails, and acrocephaly.  A brain MRI scan 
demonstrated a thin corpus callosum.  
 
Discussion 
Through an exome sequencing approach, the current study has identified five patients with novel 
single de novo ZBTB20 missense variants. These data replicate previous reports that Primrose 
syndrome missense variants cluster within the zinc finger domains and expand the clustering to 
include the third zinc finger domain where only two pathogenic variants had previously been 
reported (11). Stellachi et al. recently reported a frameshift variant outside of the zinc finger 
domains said to cause Primrose Syndrome (11). Given the findings both from the current study 
and previously reported studies, a frameshift variant would be an unusual cause of Primrose 
Syndrome. In addition, further evaluation of the phenotype in this patient suggests greater 
similarity with the 3q13.31 microdeletion syndrome than Primrose Syndrome with increased 
growth and a milder intellectual disability than that normally described in Primrose syndrome.  
In addition, this patient, facially, bears a significant resemblance to the patient reported by 
Rasmussen et al. with a 3q13.31 microdeletion, rather than patients with Primrose syndrome 
(21). 
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The identification of five additional patients with pathogenic ZBTB20 missense variants has 
increased the total number of patients with de novo ZBTB20 missense variants to 19 and has 
allowed further refinement of the Primrose syndrome phenotype (supplementary table 1). Major 
clinical features, reported in >90% of patients with Primrose syndrome, include an intellectual 
disability (most frequently in the moderate range), a characteristic facial appearance consisting 
of prominent forehead, deep set eyes, down slanting palpebral fissures, small mouth, thin upper 
lip and pointed chin and abnormal findings on brain MRI scan (most frequently abnormalities of 
the corpus callosum). Other likely clinical associations of Primrose syndrome, reported in 50-90% 
of patients with Primrose syndrome, include hearing loss (83%), hypotonia (78%), cryptorchidism 
in males (75%), macrocephaly (72%), behavioral issues (67%) and dysplastic or hypoplastic nails 
(53%). In addition, distal muscle wasting, abnormalities of glucose metabolism, contractures and 
ectopic calcification of the pinnae were reported in at least 80% of adult patients. None of these 
four clinical features were reported in the five patients in the current study. However, our oldest 
patient was only 13.4 years and so it is possible that our five patients may still develop these.  
Based on our findings and data from the fourteen previously reported patients with missense 
variants, our practice is to ensure appropriate learning and behavior support is in place and to 
refer to physiotherapy for management of hypotonia and/or contractures. We undertake a 
hearing evaluation for all our patients.  In addition, until there are longitudinal data, we are 
screening our patients for both abnormalities of glucose metabolism and thyroid abnormalities.  
All five variants occurred de novo. One variant was mosaic.  This has implications for the 
counselling of families with regard to recurrence risk.  We would counsel a 1% recurrence risk 
where a child has a de novo constitutive variant, with no evidence of mosaicism, reflecting the 
possibility of germline mosaicism and we would offer prenatal testing in future pregnancies.  In 
contrast, the risk of recurrence of a de novo mosaic variant is very low (background rate) and 
invasive prenatal testing for future pregnancies would not be recommended.   
Although the current study has allowed further refinement of the Primrose syndrome phenotype, 
the total number of patients and, in particular, the number of adults with Primrose syndrome 
remains small. However, as exome/genome sequencing becomes more accessible, it is likely that 
additional individuals, of all ages, will be identified with Primrose syndrome. This will result in an 
improving understanding of the Primrose syndrome phenotype, a greater knowledge of the long 
term syndrome complications and the implementation of optimal, consistent, evidence-based 
management.  
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Table 1: Clinical features of the five patient reported in the current study with de novo pathogenic ZBTB20 variants 
Patient details Patient identifier 1 2 3 4 5 
 Sex  Female Male Female Male Male 
 Age/years 3.0 3.9 2.3 11.3 13.4 
Variant details Nucleotide c.1749C>G c.1850T>C c.1879A>G c.1943C>T c.1967A>G 
 Amino acid p.(Cys583Trp) p.(Leu617Ser) p.(Thr627Ala) p.(Ser648Phe) p.(His656Arg) 
 Inheritance de novo de novo de novo de novo mosaic de novo 
Growth Ht/cm (SD) 99 (-0.5) 97 (-1.5) 85 (-0.8) 154.5 (+0.9) 154 (-0.1) 
 Wt/kg (SD) 15 (-0.6) 12.3 (-2.5) 10.9 (-1.2) 73.7 (+2.6) 68.3 (+1.4) 
 HC/cm (SD) 51.5 (+0.4) 53.5 (+1.9) 50.5 (+1) 61 (+5) 59 (+2.8) 
 BW/kg (SD) 2.9 (-0.3) 2.3 (-2.1) 3.0 (-0.5) 5.3 (+3.4) 2.58 (-2.1) 
 BHC/cm (SD) 36 (+2.1) 35.4 (+0.4) nk nk nk 
Learning and 
behavior 
Learning difficulties     Moderate Moderate Moderate 
Behavioral issues - Head banging - Poor sleep, tantrums, 
poor memory  
- 
Additional 
medical 
problems 
Hearing loss - + + + + 
Hypothyroid + - - - - 
Hypotonia + + + - + 
Muscle wasting - - - - - 
Contractures  nk - - - + 
Dysplastic nails - nk + - + 
Eyes - Hypermetropia, 
astigmatism, 
strabismus 
Hypermetropia, 
recurrent 
blepharoconjunctivitis 
Strabismus  - 
Cryptorchidism na + na + - 
Error glucose metabolism nk nk - nk - 
Ectopic calcification pinna - - - - - 
Other - Patent foramen ovale, 
afebrile seizure 
Joint hypermobility, 
poor/delayed 
secondary dentition, 
raised urinary calcium, 
kyphoscoliosis 
- Hyperphagia, lumbar 
lordosis 
Brain imaging Brain MRI Agenesis of the corpus 
callosum, colpocephaly 
Agenesis of the corpus 
callosum (partial) 
Normal Chiari malformation Hypoplastic corpus 
callosum 
Abbreviations:  +, present; -,  absent; nk, not known; na, not applicable; Ht height, Wt, weight; HC, head circumference; BW, birth weight; BHC, birth 
head circumference; SD, standard deviations ; GTT, abnormal glucose tolerance;  DM, diabetes mellitus
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Supplementary table 1: Table of clinical features reported in 19 patients with ZBTB20 missense variants including five patients included in the current 
study and 14 patients reported in the literature.  
 
 
Supplementary table 2. Pathogenicity evidence and ACMG classification for variants in this study 
  
Variant Inheritance  Domain Polyphen SIFT GnomAD ACMG 
classification 
c.1879A>G, 
p.(Thr627Ala) 
De novo ZnF II Probably 
damaging  
Deleterious Absent Pathogenic 
c.1749C>G, 
p.(Cys583Trp) 
De novo ZnF I Probably 
damaging  
Deleterious Absent Pathogenic 
c.1850T>C, 
p.(Leu617Ser) 
De novo ZnF II 
 
Probably 
damaging  
Deleterious Absent Pathogenic 
c.1943C>T, 
p.(Ser648Phe) 
De novo mosaic ZnF III Probably 
damaging  
Deleterious Absent 
 
Pathogenic 
c.1967A>G, 
p.(His656Arg) 
De novo ZnF III Probably 
damaging  
Deleterious Absent Pathogenic 
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Figure 1 a) schematic of ZBTB20 showing the BTB domain (blue) and the four C2H2 zinc finger domains (red). Variants identified in the current study 
are shown above the line and previously reported variants are shown below the line; b) facial appearance of ** individuals with ZBTB20 variants.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
